XML 45 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration and Licensing Agreements - Additional Information (Detail) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended				3 Months Ended
	Dec. 31, 2017 USD ($)		Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2018 CAD ($)	Mar. 31, 2018 JPY (¥)	Mar. 31, 2018 USD ($)	Jan. 02, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Current assets	$ 149,712	[1]					$ 135,320	$ 5,000
Current liabilities	17,871	[1]					13,162	1,000
Cost of revenue							464
Adjustments | ASU 2014-09
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Current assets							5,000	5,000
Current liabilities							1,000	1,000
Kyowa Hakko Kirin [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 30,000
Revenue							0
Kyowa Hakko Kirin [Member] | Adjustments | ASU 2014-09
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Current assets								5,000
Current liabilities								$ 1,000
Shanghai Fosun Pharmaceutical Industrial Development [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received	12,000
Revenue							0
Future development milestones	$ 113,000
Threshold percentage of net sales for tiered royalties	20.00%
Astra Zeneca [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received				$ 75,000
Development And Commercialization [Member] | Kyowa Hakko Kirin [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development milestones							55,000
Commercialization milestones | ¥						¥ 8.5
Development And Commercialization [Member] | Shanghai Fosun Pharmaceutical Industrial Development [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of revenue			2,400
Development And Commercialization [Member] | Astra Zeneca [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of revenue							1,000
Development And Commercialization [Member] | Knight Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							2,300
Total payments, including an up-front payment and development and sales milestones to be received					$ 25
Cost of revenue			$ 6,000				500
Termination Agreement [Member] | Astra Zeneca [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of revenue							$ 500
Termination Agreement [Member] | Knight Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of revenue				$ 9,900
[1] Derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10K for the year ended December 31, 2017.

X

- Definition

The amount of commercialization milestones payment to be received under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	ardx_CollaborativeArrangementCommercializationMilestonesPaymentToBeReceived
Namespace Prefix:	ardx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of development milestones payment to be received under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	ardx_CollaborativeArrangementDevelopmentMilestonesPaymentToBeReceived
Namespace Prefix:	ardx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of future development and commercialization milestone under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	ardx_CollaborativeArrangementFutureDevelopmentAndCommercializationMilestones
Namespace Prefix:	ardx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of upfront payments and development and sales milestones payment to be received under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	ardx_CollaborativeArrangementUpFrontPaymentAndDevelopmentAndSalesMilestonesPaymentToBeReceived
Namespace Prefix:	ardx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the threshold percentage of net sales for tiered royalties.

+ References

No definition available.

+ Details

Name:	ardx_ThresholdPercentageOfSalesForTieredRoyalties
Namespace Prefix:	ardx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

+ Details

Name:	us-gaap_AssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_CostOfRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=ardx_KyowaHakkoKirinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=ardx_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ardx_DevelopmentAndCommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ardx_TerminationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: